Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Please select a surgery type to learn more about the use of EXPAREL in procedures at your practice
EXPAREL is a cost-effective option for postsurgical pain management both in the hospital and in outpatient settings
ASCs in Tennessee
Complication rates compared favorably with those reported after standard inpatient THA
99.3% of cases did not require a transfer to the hospital for transfusion
Average surgical time was 71 minutes and total LOS was 10.8 hours
98% of cases did not require surgical intervention within a 90-day period
Freestanding ASC in Illinois
100% discharge rate to home for all patients
135 minutes of average recovery time for hip procedures*
132 minutes of average recovery time for knee procedures*
0 readmissions for postsurgical pain
ASC in New Jersey
84% of patients surveyed (n=19) reported pain level as expected and well controlled
0% of patients required an ED visit is it for uncontrolled pain and postsurgical transfusion
0% of patients experienced a reported adverse event that required prolonged care or hospitalization
98% of patients were discharged to home
80% of patients surveyed (n=19) would recommend the ASC to friends and family
16 US centers
Significantly better pain control (P=0.0381) 12 to 48 hours after surgeryâ€
78% reduction in opioid use 0 to 48 hours after surgery (P=0.0048)‡
10% of patients free of opioids at 72 hours (P<0.01)§
16 international study sites
Significantly better pain control (P<0.0001) through 48 hours after surgery
78% reduction in opioid use through 48 hours (P<0.0001)‡
13% of patients opioid free compared with 1% with placebo at 48 hours (P=0.008)
Hospital in Florida
Significantly less pain (P<0.001) on POD 1
51% less cumulative opioid use for all PODs (P<0.001)‡
50% reduction in LOS (P<0.001)
*Recovery duration started with the transfer of the patient from the operating room to the postanesthesia care unit and concluded at the discharge of the patient from the ASC.2
†Pain measured using visual analog scale.4
‡The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials.
§Compared with 0% of patients who received bupivacaine HCl alone.4
ASC, ambulatory surgery center; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty; UKA, unicondylar knee arthroplasty.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.